Anavex Life Sciences (NASDAQ: AVXL) — Company Overview, News & Financial Data
Anavex Life Sciences develops innovative therapies for neurodegenerative disorders, focusing on improving patient quality of life.
Anavex Life Sciences
Anavex Life Sciences (NASDAQ:AVXL) is a biopharmaceutical company focused on developing innovative therapies to treat neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, and Rett syndrome. Their research emphasizes the activation of the sigma-1 receptor, a unique protein that plays a key role in restoring neural cell homeostasis and promoting neuroplasticity. Anavex's pipeline showcases a range of therapeutic candidates in various stages of clinical development, aiming to address some of the most challenging medical conditions with unmet needs. The company's objectives revolve around advancing these candidates through clinical trials to demonstrate efficacy and safety, with the ultimate goal of improving the lives of patients suffering from debilitating neurological diseases.
Snapshot
Operations
Products and/or services of Anavex Life Sciences
- ANAVEX®2-73 (blarcamesine) targets Alzheimer’s disease using precision medicine.
- ANAVEX®2-73 also targets Parkinson’s disease dementia with a focus on cognitive impairment.
- Development of treatments for Rett syndrome, employing ANAVEX®2-73 to address neurological mutations.
- Researching potential therapies for epilepsy, aiming to reduce seizure frequency and severity.
- Exploring the applicability of ANAVEX®2-73 in addressing multiple sclerosis, focusing on cognitive functions and physical disability.
- Investigating innovative treatments for amyotrophic lateral sclerosis (ALS), striving to halt or reverse neurodegeneration.
Anavex Life Sciences executive team
- Sandra BoenischPrincipal Financial Officer & Treasurer
- Terrie KellmeyerInterim Chief Executive Officer
Latest news about Anavex Life Sciences
Key financials
Reported results for Anavex Life Sciences , in USD.
- Market cap
- 120.5M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.1
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -51.4M | -46.4M | |
| 0 | -52.9M | -43M | |
| 0 | -47.5M | -47.5M | |
| 0 | -51M | -48M |